{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:54:41Z","timestamp":1792702481041,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["20251445"],"award-info":[{"award-number":["20251445"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011492","name":"Jiangmen Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025YL01025"],"award-info":[{"award-number":["2025YL01025"]}],"id":[{"id":"10.13039\/501100011492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012180"],"award-info":[{"award-number":["2024A1515012180"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515011227"],"award-info":[{"award-number":["2023A1515011227"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109385","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:41:36Z","timestamp":1765870896000},"page":"109385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity"],"prefix":"10.1016","volume":"169","author":[{"given":"Wen-Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-cheng","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-kang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-kai","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie-er","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109385_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112571","article-title":"A comprehensive insight on the recent development of cyclic dependent kinase inhibitors as anticancer agents","volume":"203","author":"Marak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109385_bb0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: an overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0020","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/onc.2016.409","article-title":"A CDK2 activity signature predicts outcome in CDK2-low cancers","volume":"36","author":"McCurdy","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109385_bb0025","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in Cancer therapy: an update","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11033-018-4222-8","article-title":"Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells","volume":"45","author":"Ozfiliz-Kilbas","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2025.109385_bb0035","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/0008-5472.CAN-10-4086","article-title":"Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E","volume":"71","author":"Akli","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109385_bb0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/0929867321666141106113633","article-title":"Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents","volume":"22","author":"Chohan","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109385_bb0050","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","article-title":"Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2","volume":"131","author":"Ying","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.109385_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.36401\/JIPO-24-22","article-title":"Cyclin dependent kinase 2 (CDK2) inhibitors in oncology clinical trials: a review","volume":"8","author":"House","year":"2025","journal-title":"J. Immunother. Precis Oncol."},{"key":"10.1016\/j.bioorg.2025.109385_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/biolre\/ioaa107","article-title":"Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception\u2020","volume":"103","author":"Faber","year":"2020","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.bioorg.2025.109385_bb0065","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1080\/14796694.2024.2416382","article-title":"Targeting CDK2 to combat drug resistance in cancer therapy","volume":"20","author":"Kasirzadeh","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2025.109385_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112571","article-title":"A comprehensive insight on the recent development of cyclic dependent kinase inhibitors as anticancer agents","volume":"203","author":"Marak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0075","doi-asserted-by":"crossref","first-page":"18500","DOI":"10.1039\/C8NJ04306J","article-title":"Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review","volume":"42","author":"Deep","year":"2018","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0080","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1021\/jm4006884","article-title":"A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors","volume":"56","author":"Guck\u00fd","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0085","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2025.109385_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109385_bb0095","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/1568026620666200516152756","article-title":"Small molecule CDK inhibitors for the therapeutic Management of Cancer","volume":"20","author":"Goel","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113309","article-title":"Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: synthesis, kinase inhibition and co-crystal structure","volume":"216","author":"Jansa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0105","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1158\/1538-7445.AM2024-5709","article-title":"Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+\/HER2- breast cancer and CCNE1high ovarian cancer","volume":"84","author":"Shen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109385_bb0110","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2023.41.16_suppl.3095","article-title":"BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation","volume":"41","author":"Patel","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109385_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117503","article-title":"Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer","volume":"290","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0120","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.jmedchem.6b01254","article-title":"Cyclin-dependent kinase (CDK) inhibitors: structure-activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-Arylaminopurines","volume":"60","author":"Coxon","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0125","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","article-title":"Identification and characterization of an irreversible inhibitor of CDK2","volume":"22","author":"Anscombe","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109385_bb0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2019.06.055","article-title":"Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity","volume":"179","author":"Diao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0135","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/acs.jmedchem.4c02441","article-title":"Structure-guided discovery of novel N4-(substituted Thiazol-2-yl)-N2-(4-substituted phenyl)pyrimidine-2,4-diamines as potent CDK2 and CDK9 dual inhibitors with high Oral bioavailability","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107019","article-title":"Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy","volume":"143","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105324","article-title":"Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4\/6 inhibitors: synthesis, structure-activity relationship, and biological activity","volume":"116","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejmech.2016.04.038","article-title":"Design, synthesis and antiproliferative activity of novel 5-nitropyrimidine-2,4-diamine derivatives bearing alkyl acetate moiety","volume":"118","author":"Zhao","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2017.08.071","article-title":"Structural insights of cyclin dependent kinases: implications in design of selective inhibitors","volume":"142","author":"Kalra","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117503","article-title":"Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer","volume":"290","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109385_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113281","article-title":"Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors","volume":"215","author":"Lin","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:37:36Z","timestamp":1768937856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"alternative-id":["S0045206825012659"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109385","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109385"}}